BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

347 related articles for article (PubMed ID: 26334989)

  • 1. Decreased activation-induced cell death by EBV-transformed B-cells from a patient with autoimmune lymphoproliferative syndrome caused by a novel FASLG mutation.
    Ruiz-García R; Mora S; Lozano-Sánchez G; Martínez-Lostao L; Paz-Artal E; Ruiz-Contreras J; Anel A; González-Granado LI; Moreno-Pérez D; Allende LM
    Pediatr Res; 2015 Dec; 78(6):603-8. PubMed ID: 26334989
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Autoimmune lymphoproliferative syndrome caused by a homozygous null FAS ligand (FASLG) mutation.
    Magerus-Chatinet A; Stolzenberg MC; Lanzarotti N; Neven B; Daussy C; Picard C; Neveux N; Desai M; Rao M; Ghosh K; Madkaikar M; Fischer A; Rieux-Laucat F
    J Allergy Clin Immunol; 2013 Feb; 131(2):486-90. PubMed ID: 22857792
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Autoimmune lymphoproliferative syndrome due to somatic FAS mutation (ALPS-sFAS) combined with a germline caspase-10 (CASP10) variation.
    Martínez-Feito A; Melero J; Mora-Díaz S; Rodríguez-Vigil C; Elduayen R; González-Granado LI; Pérez-Méndez D; Sánchez-Zapardiel E; Ruiz-García R; Menchén M; Díaz-Madroñero J; Paz-Artal E; Del Orbe-Barreto R; Riñón M; Allende LM
    Immunobiology; 2016 Jan; 221(1):40-7. PubMed ID: 26323380
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel homozygous Fas ligand mutation leads to early protein truncation, abrogation of death receptor and reverse signaling and a severe form of the autoimmune lymphoproliferative syndrome.
    Nabhani S; Hönscheid A; Oommen PT; Fleckenstein B; Schaper J; Kuhlen M; Laws HJ; Borkhardt A; Fischer U
    Clin Immunol; 2014 Dec; 155(2):231-7. PubMed ID: 25451160
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Next Generation Sequencing for Detecting Somatic
    López-Nevado M; Docampo-Cordeiro J; Ramos JT; Rodríguez-Pena R; Gil-López C; Sánchez-Ramón S; Gil-Herrera J; Díaz-Madroñero MJ; Delgado-Martín MA; Morales-Pérez P; Paz-Artal E; Magerus A; Rieux-Laucat F; Allende LM
    Front Immunol; 2021; 12():656356. PubMed ID: 33995372
    [TBL] [Abstract][Full Text] [Related]  

  • 6. EBV Negative Lymphoma and Autoimmune Lymphoproliferative Syndrome Like Phenotype Extend the Clinical Spectrum of Primary Immunodeficiency Caused by STK4 Deficiency.
    Schipp C; Schlütermann D; Hönscheid A; Nabhani S; Höll J; Oommen PT; Ginzel S; Fleckenstein B; Stork B; Borkhardt A; Stepensky P; Fischer U
    Front Immunol; 2018; 9():2400. PubMed ID: 30386345
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Revisiting autoimmune lymphoproliferative syndrome caused by Fas ligand mutations.
    Maccari ME; Schneider P; Smulski CR; Meinhardt A; Pinto F; Gonzalez-Granado LI; Schuetz C; Sica MP; Gross M; Fuchs I; Kury P; Heeg M; Vocat T; Willen L; Thomas C; Hühn R; Magerus A; Lorenz M; Schwarz K; Rieux-Laucat F; Ehl S; Rensing-Ehl A
    J Allergy Clin Immunol; 2023 May; 151(5):1391-1401.e7. PubMed ID: 36621650
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential regulation of miR-146a/FAS and miR-21/FASLG axes in autoimmune lymphoproliferative syndrome due to FAS mutation (ALPS-FAS).
    Marega LF; Teocchi MA; Dos Santos Vilela MM
    Clin Exp Immunol; 2016 Aug; 185(2):148-53. PubMed ID: 27060458
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Autoimmune Lymphoproliferative Syndrome with Defective FAS or FAS-Ligand Functions.
    Rieux-Laucat F; Magérus-Chatinet A; Neven B
    J Clin Immunol; 2018 Jul; 38(5):558-568. PubMed ID: 29911256
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Loss-of-function of the protein kinase C δ (PKCδ) causes a B-cell lymphoproliferative syndrome in humans.
    Kuehn HS; Niemela JE; Rangel-Santos A; Zhang M; Pittaluga S; Stoddard JL; Hussey AA; Evbuomwan MO; Priel DA; Kuhns DB; Park CL; Fleisher TA; Uzel G; Oliveira JB
    Blood; 2013 Apr; 121(16):3117-25. PubMed ID: 23430113
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Advances in autoimmune lymphoproliferative syndromes.
    Madkaikar M; Mhatre S; Gupta M; Ghosh K
    Eur J Haematol; 2011 Jul; 87(1):1-9. PubMed ID: 21447005
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical and immunological overlap between autoimmune lymphoproliferative syndrome and common variable immunodeficiency.
    Rensing-Ehl A; Warnatz K; Fuchs S; Schlesier M; Salzer U; Draeger R; Bondzio I; Joos Y; Janda A; Gomes M; Abinun M; Hambleton S; Cant A; Shackley F; Flood T; Waruiru C; Beutel K; Siepermann K; Dueckers G; Niehues T; Wiesel T; Schuster V; Seidel MG; Minkov M; Sirkiä K; Kopp MV; Korhonen M; Schwarz K; Ehl S; Speckmann C
    Clin Immunol; 2010 Dec; 137(3):357-65. PubMed ID: 20832369
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutation of FAS, XIAP, and UNC13D genes in a patient with a complex lymphoproliferative phenotype.
    Boggio E; Aricò M; Melensi M; Dianzani I; Ramenghi U; Dianzani U; Chiocchetti A
    Pediatrics; 2013 Oct; 132(4):e1052-8. PubMed ID: 24043286
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Residual CD95-pathway function in children with autoimmune lymphoproliferative syndrome is independent from clinical state and genotype of CD95 mutation.
    Fuchs H; Posovszky C; Lahr G; van der Werff ten Bosch J; Boehler T; Debatin KM
    Pediatr Res; 2009 Feb; 65(2):163-8. PubMed ID: 18948840
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Deregulation of Fas ligand expression as a novel cause of autoimmune lymphoproliferative syndrome-like disease.
    Nabhani S; Ginzel S; Miskin H; Revel-Vilk S; Harlev D; Fleckenstein B; Hönscheid A; Oommen PT; Kuhlen M; Thiele R; Laws HJ; Borkhardt A; Stepensky P; Fischer U
    Haematologica; 2015 Sep; 100(9):1189-98. PubMed ID: 26113417
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dominant inhibition of Fas ligand-mediated apoptosis due to a heterozygous mutation associated with autoimmune lymphoproliferative syndrome (ALPS) Type Ib.
    Bi LL; Pan G; Atkinson TP; Zheng L; Dale JK; Makris C; Reddy V; McDonald JM; Siegel RM; Puck JM; Lenardo MJ; Straus SE
    BMC Med Genet; 2007 Jul; 8():41. PubMed ID: 17605793
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A homozygous Fas ligand gene mutation in a patient causes a new type of autoimmune lymphoproliferative syndrome.
    Del-Rey M; Ruiz-Contreras J; Bosque A; Calleja S; Gomez-Rial J; Roldan E; Morales P; Serrano A; Anel A; Paz-Artal E; Allende LM
    Blood; 2006 Aug; 108(4):1306-12. PubMed ID: 16627752
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunologic evaluation and genetic defects of apoptosis in patients with autoimmune lymphoproliferative syndrome (ALPS).
    Casamayor-Polo L; López-Nevado M; Paz-Artal E; Anel A; Rieux-Laucat F; Allende LM
    Crit Rev Clin Lab Sci; 2021 Jun; 58(4):253-274. PubMed ID: 33356695
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Paradoxical CD4 Lymphopenia in Autoimmune Lymphoproliferative Syndrome (ALPS).
    Lisco A; Wong CS; Price S; Ye P; Niemela J; Anderson M; Richards E; Manion M; Mystakelis H; Similuk M; Lo B; Stoddard J; Rosenzweig S; Vanpouille C; Rupert A; Maric I; Perez-Diez A; Parenti D; Burbelo PD; Rao VK; Sereti I
    Front Immunol; 2019; 10():1193. PubMed ID: 31191551
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 18.